Raymond James & Associates Bio Xcel Therapeutics, Inc. Transaction History

Raymond James & Associates

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Jul 19, 2024	SELL	$1.14 - $2.97 $911 - $2,376	-800 Reduced 4.32%	17,731 $22,000
Q1 2024 Apr 22, 2024	SELL	$1.95 - $4.04 $815 - $1,688	-418 Reduced 2.21%	18,531 $52,000
Q4 2023 Jan 16, 2024	BUY	$2.32 - $5.51 $5,039 - $11,967	2,172 Added 12.95%	18,949 $55,000
Q3 2023 Oct 24, 2023	SELL	$2.49 - $11.85 $4,658 - $22,171	-1,871 Reduced 10.03%	16,777 $42,000
Q2 2023 Jul 25, 2023	BUY	$6.39 - $28.58 $29,368 - $131,353	4,596 Added 32.71%	18,648 $124,000
Q1 2023 Apr 14, 2023	SELL	$17.7 - $33.24 $33,222 - $62,391	-1,877 Reduced 11.78%	14,052 $262,000
Q4 2022 Feb 08, 2023	BUY	$10.25 - $22.43 $40,364 - $88,329	3,938 Added 32.84%	15,929 $342,000
Q3 2022 Oct 25, 2022	SELL	$11.19 - $17.89 $3,625 - $5,796	-324 Reduced 2.63%	11,991 $142,000
Q2 2022 Aug 12, 2022	BUY	$9.03 - $21.55 $12,452 - $29,717	1,379 Added 12.61%	12,315 $163,000
Q1 2022 May 11, 2022	BUY	$15.0 - $22.83 $164,040 - $249,668	10,936 New	10,936 $229,000
Q4 2021 Feb 08, 2022	SELL	$20.12 - $35.09 $163,515 - $285,176	-8,127 Closed	0 $0
Q3 2021 Nov 02, 2021	BUY	$23.84 - $32.03 $20,836 - $27,994	874 Added 12.05%	8,127 $247,000
Q2 2021 Aug 11, 2021	BUY	$29.06 - $38.83 $210,772 - $281,633	7,253 New	7,253 $211,000
Q4 2020 Feb 12, 2021	SELL	$42.46 - $56.58 $685,729 - $913,767	-16,150 Closed	0 $0
Q3 2020 Nov 04, 2020	BUY	$37.44 - $64.63 $604,656 - $1.04 Million	16,150 New	16,150 $700,000

3.12M

22.2K

40.2K

Ticker BTAI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 28,022,500
Market Cap $9.53M
Description
BioXcel Therapeutics, Inc. is a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and prop...

Get notified when there are updates to the investment portfolio of Raymond James & Associates, based on Form 13F filings with the SEC.

Stay updated on Raymond James & Associates with notifications on news.